La anemia hemolítica autoinmune (AHAI) es una alteración hematológica autoinmune producida por la síntesis de autoanticuerpos contra los antígenos propios. Estas representam as formas mais comuns de anemia hemolítica hereditária. .. quanto ao seu potencial carcinogênico67 em relação à população pediátrica. Recibido para publicación: Aceptado para publicación: Introducción. La anemia hemolítica microangiopática se describió por prime-.
|Published (Last):||21 February 2007|
|PDF File Size:||5.35 Mb|
|ePub File Size:||6.60 Mb|
|Price:||Free* [*Free Regsitration Required]|
Indian J Med Sci. Population analysis of the alpha hemoglobin stabilizing protein AHSP gene identifies sequence variants that alter expression and function. Erythrocyte disorders in the perinatal period.
An update on anemia in less developed countries. J Pediatr,pp. J Womens Health Larchmt. In the second plasmapheresiswas required and produced remission of allthe symptomatology.
Anemia hemolítica autoinmune por hemolisina bifásica | Anales de Pediatría (English Edition)
Adhesion molecules and hydroxyurea in the pathophysiology of sickle cell disease. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease.
The etiology is still unknown,although different factors such as large von Willebrandfactor multimers and prostacyclin have been implicated.
Red blood cell defects and malaria. Pulmonary hypertension in sickle cell disease. Bienvenido a siicsalud Contacto Inquietudes. To improve our services and products, we use “cookies” own or third parties authorized to show advertising related to client preferences through the analyses of navigation customer behavior.
Previous article Next article. We present the clinical cases of two children, aged 4 and7 respectively, with TTP, but with different evolution andtreatment.
Madigan C, Pedixtria P. Free Radic Biol Med. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: Modifier genes and sickle cell anemia.
Tolentino K, Friedman JF. Effect of cytokines and chemokines on abemia neutrophil adhesion to hemooitica.
The genetics of blood disorders: hereditary hemoglobinopathies
The genetics of blood disorders: Therefore, properly designed clinical trials evaluating rituximab as salvage- and first-line-therapy for the treatment of AIHA and cold agglutinin disease are clearly warranted. You can change the settings or obtain more information by clicking here. Os autores analisaram SNP em 39 genes candidatos, em 1. Genetic insights into the clinical diversity of beta thalassaemia.
Identification of differentially expressed genes induced by hydroxyurea in reticulocytes from sickle cell anaemia patients. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Laboratorydata typically reveal hemolytic anemia, with schistocyteson the peripheral smear, diminished serum haptoglobin,and thrombocytopenia.
Cytokines and plasma factors in sickle cell disease. Ion transport pathology in the mechanism of sickle cell dehydration.
Am J Trop Med Hyg. SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field. The anti-CD20 hemoitica antibody rituximab has gained widespread acceptance in the management of haematologic disorders with autoantibodies production. Normality has been maintained for36 and 24 months respectively, and the children have presentedno clinico-biological alterations.
There was a problem providing the content you requested
Are you a health professional able to prescribe or dispense drugs? This item has received. Distinct HLA associations by aemia subtype in children with sickle cell anemia.
The genomics of new drugs in sickle cell disease. Estella Aguado b. Davies SC, Gilmore A. Overt and incomplete silent cerebral pediatrai in sickle cell anemia: Successful treatment of recurrent thrombotic thrombocytopenic purpura with plasmapheresis and vincristine.
HPLC studies in hemoglobinopathies.
The treatment of these autoimmune haemolytic anaemias with rituximab requires authorisation by the Spanish Ministry of Health for compassionate use.
Int J Biochem Cell Biol. Um novo quelante oral, o deferasirox, foi recentemente aprovado nos EUA e no Brasil.